• Assaf Moore, Yael Bar, Corinne Maurice-Dror, Inbar Finkel, Hadar Goldvaser, Elizabeth Dudnik, Daniel A Goldstein, Noa Gordon, Salem Billan, Orit Gutfeld, Ido Wolf, and Aron Popovtzer.
• Institute of Oncology, Davidoff Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva.
• Medicine (Baltimore). 2021 Jun 25; 100 (25): e26388e26388.

AbstractRadioiodine-refractory thyroid cancers (IRTCs) are uncommon and have a poor prognosis. Treatment options for radioiodine-refractory and anaplastic tumors (ATCs) are limited. Although the genomic landscape of thyroid cancer has been studied, there is little evidence on whether next-generation sequencing (NGS) findings translate to tumor control.We analyzed all patients with IRTC and ATC who underwent commercially available NGS in 3 cancer centers.Twenty-two patients were identified, 16 patients with IRTCs and 6 patients with ATCs. Eighteen (82%) had targetable findings in NGS, nine patients were treated accordingly. Median progression-free survival for targeted treatment was 50 months [95% confidence interval (CI95%) 9.8-66.6] and2 months (CI95% 0.2-16.5) for IRTC and ATC, respectively. Of 4 patients who achieved durable responses of 7 to 50 months, 2 are ongoing. The estimated median OS of IRTC receiving targeted treatment was not reached (CI95% 89.7-111.4 months) and was 77.8 months (CI95% 52.5-114.6) for patients treated conventionally (P = .3).NGS may detect clinically significant genetic alterations and benefit patients with advanced thyroid cancers.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

60 keywords...

hide…